APA (7th ed.) Citation

Nester, C. M., Bomback, A. S., Ariceta, G., Delmas, Y., Dixon, B. P., Gale, D. P., . . . Zecher, D. (2025). VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN. Immunobiology, 230(4), N.PAG. https://doi.org/10.1016/j.imbio.2025.153039

Chicago Style (17th ed.) Citation

Nester, Carla M., et al. "VALIANT: Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent C3G or Primary (idiopathic) IC-MPGN." Immunobiology 230, no. 4 (2025): N.PAG. https://doi.org/10.1016/j.imbio.2025.153039.

MLA (9th ed.) Citation

Nester, Carla M., et al. "VALIANT: Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent C3G or Primary (idiopathic) IC-MPGN." Immunobiology, vol. 230, no. 4, 2025, p. N.PAG, https://doi.org/10.1016/j.imbio.2025.153039.